33 results about "Histidine kinase" patented technology

Compounds that competitively inhibit binding of CSP to S. mutans histidine kinase are provided. The compounds are preferably a peptide or an antibody, and are preferably a derivative of [SEQ ID NO:2], a fragment of [SEQ ID NO:2] or a derivative of a fragment of [SEQ ID NO:2]. Methods of making these compounds and their use for inhibiting the growth of S. mutans, for inhibiting dental caries, and for improving dental health are also disclosed.

The invention discloses a method for improving a nisin induction efficiency in a lactic acid bacteria NICE expression system. According to the method disclosed by the invention, the sensing activity of nisin is enhanced by conducting mutation transformation on receptor histidine kinase NisK of nisin molecules of an inducer. Experiments prove that through nisin induction of a same concentration, the expression amount of reporter protein is obviously increased and the nisin induction efficiency is remarkably enhanced after the NisK mutation transformation; therefore, the method disclosed by the invention has a quite important significance for improving the expression amount of heterologous protein, declining the concentration of the inducer and reducing the complexity of constructing the system by virtue of the NICE system.

The invention discloses a protein for regulating Cronobacter sakazakii's resistance to high stress, its encoding gene and application. The gene has the sequence shown in SEQ ID NO:2. The invention uses genetic engineering technology to knock out the high pressure resistance gene CpxA of Cronobacter sakazakii, so that the expression of histidine kinase in it is significantly reduced, thereby significantly reducing the integrity of the cell membrane of Cronobacter sakazakii, so that the sakazakii The anti-stress performance of Cronobacter sakazakii is greatly weakened, which can not only effectively inhibit the formation of Cronobacter sakazakii biofilm, but also achieve better killing effect of Cronobacter sakazakii under lower pressure. There are broad application prospects in other fields.

The invention discloses a Clostridium modified by a kinase gene with a phosphorylation function and its application; the method is a method for improving the production of butanol through the gene modification of a kinase with a phosphorylation function, specifically knocking out phosphorylation in Clostridium The function obtains the kinase (including histidine kinase, serine kinase, threonine kinase) gene, thereby regulating the downstream gene expression. After knocking out or overexpressing the kinase gene with phosphorylation function in the present invention, the butanol output of the mutant strain has a significant change compared with the wild strain, and some kinases participate in spore formation and cell morphology changes, so that the Clostridium cells maintain a high vitality state, Thereby improving the butanol synthesis capacity of cells. The Clostridium modified by the phosphorylation kinase gene of the present invention has a good application prospect in the production of butanol.

Provided herein are microorganisms engineered with hybrid receptors and genetic circuits. Also provided are hybrid receptors having a CqsS polypeptide and a heterologous histidine kinase domain of a two-component system. Methods for using engineered microorganisms to sense and destroy pathogens (e.g., Vibrio cholerae) are also provided.

The invention relates to a drug screening model taking histidine kinase AgrC as a target spot, belonging to the field of biological medicines. A construction method of the drug screening model comprises the following steps: (1) extracting and purifying AgrC protein; (2) determining the concentration of AgrC protein; (3) preparing lipidosome by taking DOPC, DPPA and CHOL as raw materials; (4) inserting the extracted and purified AgrC protein into the lipidosome by adopting a surfactant-mediating method, thus forming protein lipidosome; and (5) constructing the drug screening model taking the histidine kinase AgrC as the target spot. The constructed drug screening model is suitable for screening drug monomeric compounds having a strong inhibiting effect for histidine kinase AgrC, and the screened compounds are definite in acting sites; the drug screening model has the advantages of high flux, strong specificity and operation convenience and rapidness when used for screening the drug monomeric compounds.